GIST | Clinical

Continued PFS, OS Benefit Seen With Ripretinib in Advanced GIST

September 19, 2020

For patients with advanced gastrointestinal stromal tumors, there was continued clinically meaningful benefit with the novel broad-spectrum KIT and PDGFRα inhibitor ripretinib in the fourth line or later, according to updated data from the randomized phase 3 INVICTUS trial presented at the 2020 ESMO Virtual Congress.

Binimetinib Added to Standard of Care Elicits Responses in Advanced GIST

July 20, 2020

In an interview with Targeted Oncology, Ping Chi, MD medical oncologist, Geoffrey Beene Junior Faculty chair, Memorial Sloan Kettering Cancer Center, discussed the phase 2 study of binimetinib in combination with imatinib in patients with untreated advanced GIST.

Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors

July 01, 2020

Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.